Get started
Work

Associations between glucocorticoid use and major adverse cardiovascular events in patients with prostate cancer receiving antiandrogen: a retrospective cohort study

Year: 2024
Type: article
Study design: Observational Study
Abstract: BACKGROUND: Prednisolone/prednisone coadministration with abiraterone may explain abiraterone-related increase in cardiovascular risk. We explored this postulation and glucocorticoid's association with cardiovascular risk. METHODS: Patients with prostate cancer on androgen deprivation therapy and enzalutamide, or abiraterone with 5 mg (ABI + P5) or 10 mg (ABI + P10) daily total prednisolone/prednisone were followed up for major adverse cardiovascular events (MACE). RESULTS: We analyzed 933 patients. ABI + P10, but not enzalutamide, had higher risk of MACE than ABI + P5. Cumulative glucocorticoid dose before enzalutamide/abiraterone initiation was associated with MACE. CONCLUSIONS: Prednisolone/prednisone coadministration with abiraterone likely contributed to abiraterone-related increased cardiovascular risk. Prevalent cumulative glucocorticoid dose was associated with cardiovascular risk.
DOI: 10.1038/s41391-024-00889-x
Authors: Jeffrey Shi Kai Chan, Yan Hiu Athena Lee, Chi Ho Leung, David Ka Wai Leung, Edward Christopher Dee, Kenrick Ng, Gary Tse, Chi Fai Ng
Institutions: Chinese University of Hong Kong, Memorial Sloan Kettering Cancer Center, Barts Cancer Institute, Second Hospital of Tianjin Medical University, Kent and Medway Medical School, Tianjin Medical University, Hong Kong Metropolitan University
Language: English
Field: Medicine
Open Access status: hybrid
Estimated APC paid: $4,990
OpenAlex ID: W4402397991
FWCI: 1.522
Cites: 10
Cited by: 6
Related to: 10